MHB036C given with other cancer medicines for advanced lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a first-in-human, open-label Phase 1/2 program testing MHB036C in combination with MHB039A, Furmonertinib, Carboplatin, or other anti-tumor therapies in patients with advanced lung cancer. The trial has a dose-escalation stage with DLT and PK expansion cohorts to identify the maximum tolerated dose and characterize pharmacokinetics and safety. Based on safety, PK, and preliminary antitumor signals from completed dose levels, a dose-expansion stage will enroll patients with specific types of advanced lung cancer to further evaluate safety and preliminary efficacy. The study requires measurable disease by RECIST v1.1 and adequate organ function, and is open-label with multiple combination regimens.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Voluntarily agrees to participate in the study and signs the informed consent form.
2. Age ≥ 18 years and≤75 years, no restriction on gender.
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
4. Estimated life expectancy ≥ 3 months.
5. For the dose escalation stage: Histologically or cytologically confirmed advanced solid tumors that are refractory to standard therapy, intolerant to standard therapy, or have no standard treatment options.
6. For the dose expansion stage: Histologically or cytologically confirmed locally advanced or metastatic advanced solid tumors, not suitable for radical surgery and/or radical concurrent/sequential radiotherapy and chemotherapy.
7. At least one measurable lesion per RECIST v1.1 criteria.
8. Adequate bone marrow reserve and organ function.
9. Eligible participants of childbearing potential (males and females) must agree to take highly reliable contraceptive measures with their partners during the study and within at least 12 weeks after the last dose.

   \-

Exclusion Criteria:

1. Small cell lung cancer (SCLC) components in the histopathology.
2. History of ≥2 primary malignancies within 5 years prior to informed consent.
3. Received chemotherapy within 3 weeks, radiotherapy within 4 weeks, or biologic, endocrine, or immunotherapy within 4 weeks before first study dose.
4. Medication of other unmarketed investigational drugs or therapies within 4 weeks before dosing.
5. Brain metastases, leptomeningeal disease, brainstem metastases, or spinal cord compression.
6. Underwent major organ surgery (excluding biopsy) or significant trauma within 4 weeks before the first dose of investigational drug or requiring elective surgery during the study.
7. Previous or concurrent gastrointestinal perforation, surgical procedures and wound healing complications, as well as bleeding events.
8. Received intravenous thrombolysis treatment within 2 weeks, except for preventive anticoagulation and antiplatelet therapy.
9. Vaccinated within 4 weeks before dosing.
10. Treated with systemic corticosteroids within 14 days before dosing.
11. Severe impairment of pulmonary function; interstitial lung disease or a history of pneumonia requiring steroid treatment; previous left or right pneumonectomy.
12. Active systemic infection requiring treatment within 7 days before dosing.
13. Uncontrolled third-space effusion.
14. Serious cardiovascular or cerebrovascular diseases.
15. Known hypersensitivity or delayed allergic reaction to the investigational product or its components.
16. Drug abuse or other medical/psychiatric condition that may interfere with study participation or results.
17. Known alcohol or drug dependence.
18. Pregnant or breastfeeding women, or individuals planning to conceive. -

Where it's running

• Shanghai Chest Hospital
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: CMO/ Senior Vice President of R&D
• Email: jwshi@minghuipharma.com
• Phone: 86 0571-86963293

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nurse-led support for caregivers of older adults with advanced lung cancer

  This study tests a nurse-led care and resource system to support older adults with advanced lung cancer and their family caregivers.

  Recruiting at 2 sites National Taiwan University Hospital · Taipei, Taipei and 1 other locations · NCT07708870

• Managing chemotherapy side effects with a smartphone symptom app plus telenursing

  This trial tests whether a smartphone symptom-reporting app combined with a standardized telenursing program helps adults starting first-cycle chemotherapy for gastric, lung, breast, or colon cancer manage treatment side effects.

  Recruiting at 4 sites Ulsan University Hospital · Busan and 4 other locations · NCT07405931

• Tiered Palliative Care for Patients with Advanced Heart Failure or Cancer

  This trial tests a home-based, tiered palliative care program to see if more personalized support improves symptoms and quality of life for adults with advanced heart failure or certain advanced cancers.

  Recruiting at 5 sites Icahn School of Medicine at Mount Sinai · Astoria, New York and 4 other locations · NCT07391956

• TQB6411 injection for advanced lung cancer.

  This trial will test whether TQB6411 injection is safe and can help people with advanced lung cancer.

  Recruiting Phase 1/2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 37 other locations · NCT07367529

• JS212 combo therapy for advanced lung cancer

  This trial tests JS212 with different partners to see if it can help adults with advanced non-small cell or extensive small cell lung cancer.

  Recruiting Phase 2 Shanghai Junshi Bioscience Co., Ltd. · Shanghai, Shanghai Municipality · NCT07309276

• PROMOTE mobile app to improve physical function and wellbeing in lung cancer survivors

  This project tests whether the PROMOTE mobile app can help adults with stage I–III non-small cell lung cancer undergoing curative chemotherapy improve their physical function and overall wellbeing.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT07227623

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.